Castle Biosciences (CSTL) Stock Forecast, Price Target & Predictions
CSTL Stock Forecast
Castle Biosciences stock forecast is as follows: an average price target of $38.00 (represents a 21.87% upside from CSTL’s last price of $31.18) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CSTL Price Target
The average price target for Castle Biosciences (CSTL) is $38.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $41.00 to $35.00. This represents a potential 21.87% upside from CSTL's last price of $31.18.
CSTL Analyst Ratings
According to 3 Wall Street analysts, Castle Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for CSTL stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Castle Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 06, 2024 | Sung Ji Nam | BTIG | $35.00 | $26.24 | 33.38% | 12.25% |
| Nov 04, 2022 | Catherine Schulte Analyst | Robert W. Baird | $41.00 | $24.72 | 65.86% | 31.49% |
The latest Castle Biosciences stock forecast, released on Aug 06, 2024 by Sung Ji Nam from BTIG, set a price target of $35.00, which represents a 33.38% increase from the stock price at the time of the forecast ($26.24), and a 12.25% increase from CSTL last price ($31.18).
Castle Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $35.00 | $35.00 |
| Last Closing Price | $31.18 | $31.18 | $31.18 |
| Upside/Downside | -100.00% | 12.25% | 12.25% |
In the current month, the average price target of Castle Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Castle Biosciences's last price of $31.18. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 06, 2024 | BTIG | Buy | Buy | Hold |
| May 03, 2024 | Lake Street | Buy | Buy | Hold |
| Jun 15, 2023 | BTIG | Buy | Buy | Hold |
| Jun 06, 2023 | Canaccord Genuity | Buy | Buy | Hold |
| Jan 05, 2023 | Scotiabank | - | Sector Outperform | Initialise |
Castle Biosciences's last stock rating was published by BTIG on Aug 06, 2024. The company gave CSTL a "Buy" rating, the same as its previous rate.
Castle Biosciences Financial Forecast
Castle Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $66.12M | $61.49M | $50.14M | $42.04M | $38.34M | $37.01M | - | $26.85M | $25.04M | $23.48M | $22.76M | $22.81M | $17.30M | $15.22M | $12.71M | $17.42M | $17.63M | $14.77M |
| Avg Forecast | $69.61M | $67.08M | $69.10M | $63.25M | $67.74M | $65.85M | $65.39M | $58.67M | $57.73M | $78.93M | $69.37M | $66.55M | $56.28M | $48.57M | $44.19M | $37.41M | $37.12M | $34.76M | $28.37M | $25.23M | $23.74M | $22.97M | $19.11M | $16.72M | $15.74M | $15.00M | $8.80M | $13.72M | $11.74M | $9.45M |
| High Forecast | $77.62M | $74.79M | $77.05M | $70.53M | $75.53M | $73.43M | $72.91M | $65.42M | $64.37M | $88.01M | $77.35M | $74.20M | $61.77M | $54.16M | $49.28M | $41.72M | $41.39M | $38.75M | $28.37M | $26.16M | $24.61M | $23.82M | $19.81M | $17.33M | $16.32M | $15.55M | $9.12M | $14.22M | $12.17M | $9.80M |
| Low Forecast | $52.92M | $50.99M | $52.54M | $48.09M | $51.50M | $50.06M | $49.71M | $44.61M | $43.89M | $60.00M | $52.74M | $50.59M | $50.77M | $36.93M | $33.60M | $28.44M | $28.22M | $26.42M | $28.37M | $24.77M | $23.30M | $22.55M | $18.75M | $16.41M | $15.45M | $14.72M | $8.64M | $13.47M | $11.52M | $9.28M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.17% | 1.27% | 1.13% | 1.12% | 1.03% | 1.06% | - | 1.06% | 1.05% | 1.02% | 1.19% | 1.36% | 1.10% | 1.01% | 1.45% | 1.27% | 1.50% | 1.56% |
Castle Biosciences's average Quarter revenue forecast for Mar 24 based on 4 analysts is $66.55M, with a low forecast of $50.59M, and a high forecast of $74.20M. CSTL's average Quarter revenue forecast represents a 0.65% increase compared to the company's last Quarter revenue of $66.12M (Dec 23).
Castle Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $3.12M | $-9.64M | $-21.16M | $-26.29M | $-18.64M | $-17.47M | - | $-22.34M | $-13.71M | $-10.70M | $-8.15M | $-4.05M | $-4.25M | $-3.76M | $-505.00K | $1.43M | $2.99M | $7.03M |
| Avg Forecast | $-16.63M | $-16.03M | $-16.51M | $-15.11M | $-16.19M | $-15.73M | $-15.62M | $-14.02M | $-13.79M | $-18.86M | $-16.57M | $-17.13M | $-13.45M | $-11.61M | $-10.56M | $-15.57M | $-8.87M | $-9.71M | $-6.78M | $-14.16M | $-18.11M | $-8.83M | $-6.75M | $-5.10M | $-3.76M | $-2.57M | $-818.10K | $2.82M | $-2.80M | $-2.26M |
| High Forecast | $-12.65M | $-12.18M | $-12.55M | $-11.49M | $-12.31M | $-11.96M | $-11.88M | $-10.66M | $-10.49M | $-14.34M | $-12.60M | $-13.70M | $-12.13M | $-8.82M | $-8.03M | $-12.46M | $-6.74M | $-7.77M | $-6.78M | $-11.32M | $-14.49M | $-7.06M | $-5.40M | $-4.08M | $-3.69M | $-2.06M | $-654.48K | $3.39M | $-2.75M | $-2.22M |
| Low Forecast | $-18.55M | $-17.87M | $-18.41M | $-16.85M | $-18.05M | $-17.54M | $-17.42M | $-15.63M | $-15.38M | $-21.03M | $-18.48M | $-20.55M | $-14.76M | $-12.94M | $-11.77M | $-18.69M | $-9.89M | $-11.65M | $-6.78M | $-16.99M | $-21.73M | $-10.59M | $-8.10M | $-6.12M | $-3.90M | $-3.09M | $-981.72K | $2.26M | $-2.91M | $-2.34M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.23% | 0.83% | 2.00% | 1.69% | 2.10% | 1.80% | - | 1.58% | 0.76% | 1.21% | 1.21% | 0.79% | 1.13% | 1.46% | 0.62% | 0.51% | -1.07% | -3.11% |
4 analysts predict CSTL's average Quarter EBITDA for Mar 24 to be $-17.13M, with a high of $-13.70M and a low of $-20.55M. This is -649.17% lower than Castle Biosciences's previous annual EBITDA (Dec 23) of $3.12M.
Castle Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-2.58M | $-6.91M | $-18.78M | $-29.20M | $-20.62M | $-18.81M | - | $-24.62M | $-6.43M | $-11.79M | $-8.79M | $-4.28M | $-4.89M | $-4.59M | $-1.38M | $570.00K | $2.05M | $5.85M |
| Avg Forecast | $-6.39M | $-9.32M | $-7.39M | $-11.47M | $-14.43M | $-16.64M | $-16.63M | $-22.08M | $-22.01M | $-882.26K | $-7.72M | $-18.88M | $-16.16M | $-21.96M | $-26.30M | $-17.17M | $-24.07M | $-10.70M | $-20.94M | $-15.61M | $-8.50M | $-9.73M | $-7.28M | $-5.40M | $-3.29M | $-3.13M | $-2.23M | $1.13M | $-4.26M | $11.41M |
| High Forecast | $-4.40M | $-6.42M | $-5.09M | $-7.89M | $-9.93M | $-11.46M | $-11.45M | $-15.20M | $-15.15M | $-607.29K | $-5.32M | $-15.11M | $-13.85M | $-15.11M | $-18.10M | $-13.73M | $-16.57M | $-8.56M | $-20.94M | $-12.48M | $-6.80M | $-7.78M | $-5.82M | $-4.32M | $-3.21M | $-2.51M | $-1.78M | $1.35M | $-4.16M | $13.69M |
| Low Forecast | $-7.35M | $-10.71M | $-8.50M | $-13.18M | $-16.58M | $-19.13M | $-19.12M | $-25.38M | $-25.30M | $-1.01M | $-8.88M | $-22.66M | $-18.28M | $-25.24M | $-30.23M | $-20.60M | $-27.67M | $-12.84M | $-20.94M | $-18.73M | $-10.19M | $-11.67M | $-8.73M | $-6.48M | $-3.45M | $-3.76M | $-2.67M | $902.88K | $-4.46M | $9.12M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.16% | 0.31% | 0.71% | 1.70% | 0.86% | 1.76% | - | 1.58% | 0.76% | 1.21% | 1.21% | 0.79% | 1.49% | 1.46% | 0.62% | 0.51% | -0.48% | 0.51% |
Castle Biosciences's average Quarter net income forecast for Jun 20 is $-2.23M, with a range of $-2.67M to $-1.78M. CSTL's average Quarter net income forecast represents a -491.07% decrease compared to the company's last Quarter net income of $570.00K (Mar 20).
Castle Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $44.09M | $44.62M | $44.68M | $46.76M | $38.43M | $36.63M | - | $30.45M | $25.16M | $22.59M | $20.82M | $18.16M | $13.08M | $13.59M | $8.51M | $11.08M | $9.85M | $7.12M |
| Avg Forecast | $57.40M | $55.31M | $56.98M | $52.16M | $55.86M | $54.30M | $53.92M | $48.38M | $47.61M | $65.08M | $57.20M | $23.35M | $46.41M | $40.05M | $36.44M | $21.23M | $30.61M | $20.50M | $23.39M | $19.30M | $19.57M | $18.64M | $17.23M | $13.79M | $12.98M | $9.28M | $7.25M | $11.31M | $9.68M | $7.80M |
| High Forecast | $64.01M | $61.68M | $63.54M | $58.16M | $62.29M | $60.55M | $60.13M | $53.95M | $53.08M | $72.57M | $63.78M | $28.03M | $50.94M | $44.66M | $40.64M | $25.48M | $34.13M | $24.61M | $23.39M | $23.16M | $20.29M | $22.37M | $20.68M | $14.29M | $13.46M | $11.14M | $7.52M | $11.73M | $10.03M | $8.08M |
| Low Forecast | $43.64M | $42.05M | $43.32M | $39.65M | $42.47M | $41.28M | $41.00M | $36.78M | $36.19M | $49.48M | $43.49M | $18.68M | $41.87M | $30.45M | $27.71M | $16.99M | $23.27M | $16.40M | $23.39M | $15.44M | $19.21M | $14.91M | $13.79M | $13.53M | $12.74M | $7.42M | $7.12M | $11.10M | $9.50M | $7.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.95% | 1.11% | 1.23% | 2.20% | 1.26% | 1.79% | - | 1.58% | 1.29% | 1.21% | 1.21% | 1.32% | 1.01% | 1.46% | 1.17% | 0.98% | 1.02% | 0.91% |
Castle Biosciences's average Quarter SG&A projection for Mar 24 is $23.35M, based on 4 Wall Street analysts, with a range of $18.68M to $28.03M. The forecast indicates a -47.03% fall compared to CSTL last annual SG&A of $44.09M (Dec 23).
Castle Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.10 | $-0.26 | $-0.70 | $-1.10 | $-0.78 | $-0.71 | - | $-0.97 | $-0.25 | $-0.47 | $-0.35 | $-0.17 | $-0.23 | $-0.23 | $-0.08 | $0.03 | $0.12 | $0.43 |
| Avg Forecast | $-0.22 | $-0.32 | $-0.26 | $-0.40 | $-0.50 | $-0.58 | $-0.58 | $-0.77 | $-0.77 | $-0.03 | $-0.27 | $-0.33 | $-0.56 | $-0.76 | $-0.92 | $-0.89 | $-0.84 | $-0.88 | $-0.76 | $-0.71 | $-0.47 | $-0.41 | $-0.33 | $-0.23 | $-0.12 | $-0.11 | $-0.40 | $-0.15 | $-0.16 | $-0.30 |
| High Forecast | $-0.15 | $-0.22 | $-0.18 | $-0.27 | $-0.35 | $-0.40 | $-0.40 | $-0.53 | $-0.53 | $-0.02 | $-0.18 | $-0.23 | $-0.48 | $-0.53 | $-0.63 | $-0.61 | $-0.58 | $-0.61 | $-0.76 | $-0.69 | $-0.46 | $-0.40 | $-0.32 | $-0.23 | $-0.12 | $-0.11 | $-0.39 | $-0.14 | $-0.15 | $-0.30 |
| Low Forecast | $-0.26 | $-0.37 | $-0.30 | $-0.46 | $-0.58 | $-0.67 | $-0.67 | $-0.88 | $-0.88 | $-0.04 | $-0.31 | $-0.38 | $-0.64 | $-0.88 | $-1.05 | $-1.02 | $-0.96 | $-1.01 | $-0.76 | $-0.74 | $-0.49 | $-0.42 | $-0.35 | $-0.25 | $-0.13 | $-0.12 | $-0.42 | $-0.16 | $-0.17 | $-0.32 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.17% | 0.34% | 0.76% | 1.24% | 0.93% | 0.81% | - | 1.37% | 0.53% | 1.16% | 1.05% | 0.73% | 1.89% | 2.01% | 0.20% | -0.20% | -0.76% | -1.41% |
According to 2 Wall Street analysts, Castle Biosciences's projected average Quarter EPS for Jun 20 is $-0.40, with a low estimate of $-0.42 and a high estimate of $-0.39. This represents a -1425.00% decrease compared to CSTL previous annual EPS of $0.03 (Mar 20).
Castle Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LMDX | LumiraDx | $0.02 | $1.50 | 7400.00% | Buy |
| STIM | Neuronetics | $0.73 | $8.00 | 995.89% | Buy |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| GH | Guardant Health | $26.79 | $57.27 | 113.77% | Buy |
| XGN | Exagen | $2.96 | $6.00 | 102.70% | Buy |
| BDSX | Biodesix | $1.77 | $3.00 | 69.49% | Buy |
| PSNL | Personalis | $5.69 | $7.75 | 36.20% | Hold |
| CSTL | Castle Biosciences | $31.18 | $38.00 | 21.87% | Buy |
| CDNA | CareDx | $28.87 | $31.00 | 7.38% | Buy |
| NTRA | Natera | $126.51 | $114.38 | -9.59% | Buy |
| TWST | Twist Bioscience | $46.95 | $41.20 | -12.25% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
CSTL Forecast FAQ
Is Castle Biosciences a good buy?
Yes, according to 3 Wall Street analysts, Castle Biosciences (CSTL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of CSTL's total ratings.
What is CSTL's price target?
Castle Biosciences (CSTL) average price target is $38 with a range of $35 to $41, implying a 21.87% from its last price of $31.18. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Castle Biosciences stock go up soon?
According to Wall Street analysts' prediction for CSTL stock, the company can go up by 21.87% (from the last price of $31.18 to the average price target of $38), up by 31.49% based on the highest stock price target, and up by 12.25% based on the lowest stock price target.
Can Castle Biosciences stock reach $50?
CSTL's average twelve months analyst stock price target of $38 does not support the claim that Castle Biosciences can reach $50 in the near future.
What are Castle Biosciences's analysts' financial forecasts?
Castle Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $257.65M (high $287.3M, low $195.88M), average EBITDA is $-61.564M (high $-46.805M, low $-68.647M), average net income is $-69.786M (high $-48.036M, low $-80.224M), average SG&A $212.47M (high $236.91M, low $161.53M), and average EPS is $-2.428 (high $-1.672, low $-2.792). CSTL's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $269.04M (high $299.99M, low $204.54M), average EBITDA is $-64.285M (high $-48.873M, low $-71.681M), average net income is $-34.575M (high $-23.799M, low $-39.746M), average SG&A $221.86M (high $247.38M, low $168.67M), and average EPS is $-1.203 (high $-0.828, low $-1.383).
Did the CSTL's actual financial results beat the analysts' financial forecasts?
Based on Castle Biosciences's last annual report (Dec 2023), the company's revenue was $219.79M, beating the average analysts forecast of $186.45M by 17.88%. Apple's EBITDA was $10.62M, missing the average prediction of $-51.184M by -120.75%. The company's net income was $-57.466M, missing the average estimation of $-81.583M by -29.56%. Apple's SG&A was $180.15M, beating the average forecast of $144.14M by 24.99%. Lastly, the company's EPS was $-2.14, missing the average prediction of $-3.132 by -31.67%. In terms of the last quarterly report (Dec 2023), Castle Biosciences's revenue was $66.12M, beating the average analysts' forecast of $56.28M by 17.49%. The company's EBITDA was $3.12M, missing the average prediction of $-13.447M by -123.19%. Castle Biosciences's net income was $-2.58M, missing the average estimation of $-16.161M by -84.04%. The company's SG&A was $44.09M, missing the average forecast of $46.41M by -5.00%. Lastly, the company's EPS was $-0.0954, missing the average prediction of $-0.562 by -83.04%